Clinical trials: Still Disease
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis…
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus
- Trial name
- EMERALD (NCT05001737)
- Testing
- Emapalumab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 33 people
- Sponsor
- Swedish Orphan Biovitrum
Adult Onset Still's Disease
Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD
This study was designed to evaluate the efficacy and safety of canakinumab administered subcutaneously every 4 weeks for at least 48 weeks in Japanese patients with Adult-Onset Still's Disease (AOSD).
- Trial name
- NCT04717635
- Testing
- Canakinumab
- Where
- 9 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Macrophage Activation Syndrome (MAS) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset…
- Conditions
- Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
- Trial name
- NCT03311854
- Testing
- Emapalumab
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- Swedish Orphan Biovitrum
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)
The aim of this study is to demonstrate the efficacy and to evaluate the safety, pharmacokinetics (PK) and immunogenicity of anakinra in patients with newly diagnosed Still's disease, including SJIA (Systemic juvenile idiopathic…
- Trial name
- anaSTILLs (NCT03265132)
- Testing
- anakinra
- Where
- 39 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Swedish Orphan Biovitrum